Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin97.8%+0.8pp97.8%+0.5pp97.4%-0.7pp97%-1.5pp96.9%-1.7pp
Operating margin-43.1%-49.7pp39%+39.5pp12.7%+22.6pp9.7%+25.5pp6.6%+31.9pp
Net margin-51.7%-41.1pp30.2%+49.9pp-1.5%+28.5pp-6.4%+31.8pp-10.6%+48.1pp
Efficiency
Asset turnover1.9×+0.8×1.7×+0.8×1.3×+0.5×1.2×+0.4×1.1×+0.3×
Liquidity
Current ratio1.9×-1.0×2.1×-0.6×1.9×-0.9×2.2×-0.6×2.9×-0.8×
Per Share
Book value per share-$2.29-8.9%-$0.55+76.3%-$1.76+22.1%-$1.92+16.8%-$2.10+9.1%
Valuation
Market capitalization$2.39B+52.3%$1.64B+5.5%$1.59B+1.3%$2.08B+62.9%$1.57B+49.7%
Price / sales2.7×-0.4×1.9×-1.6×2.7×-1.2×3.7×+0.4×3.1×+0.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are BioCryst Pharmaceuticals's profit margins?
BioCryst Pharmaceuticals (BCRX) runs a 97.8% gross margin and a -43.1% operating margin, with a -51.7% net margin.
Where do BioCryst Pharmaceuticals's ratios come from?
Every ratio is computed from BioCryst Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.